Hughes Christine A, Freitas Andrea, Miedzinski Lilly J
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alta.
CMAJ. 2007 Aug 14;177(4):357-9. doi: 10.1503/cmaj.061284.
Drug interactions involving protease inhibitors are common. Protease inhibitors are well known inhibitors of the 3A4 isozyme of cytochrome P450. Select protease inhibitors, including co-formulated lopinavir/ritonavir, may induce glucuronidation or the activity of other CYP450 isozymes. We describe the case of a patient taking warfarin who experienced a significantly decreased international normalized ratio after the initiation of antiretroviral therapy that included lopinavir/ritonavir. We review the possible mechanisms of this interaction and the reported interactions between warfarin and other protease inhibitors.
涉及蛋白酶抑制剂的药物相互作用很常见。蛋白酶抑制剂是细胞色素P450 3A4同工酶的著名抑制剂。某些蛋白酶抑制剂,包括复方洛匹那韦/利托那韦,可能会诱导葡萄糖醛酸化或其他细胞色素P450同工酶的活性。我们描述了一名服用华法林的患者,在开始包含洛匹那韦/利托那韦的抗逆转录病毒治疗后,国际标准化比值显著降低的病例。我们回顾了这种相互作用的可能机制以及华法林与其他蛋白酶抑制剂之间已报道的相互作用。